[{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Capital Health, Canada | Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Iron","moa":"Hemoglobin (HB)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Capital Health, Canada | Dalhousie University","highestDevelopmentStatusID":"10","companyTruncated":"Nova Scotia Health Authority \/ Capital Health, Canada | Dalhousie University"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Endo International"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clementia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clementia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clementia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clementia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clementia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clementia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clementia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clementia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clementia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clementia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clementia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clementia Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          January 05, 2021

                          Lead Product(s) : Abaloparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Endo International

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Palovarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myositis Ossificans.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 18, 2017

                          Lead Product(s) : Palovarotene

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Iron is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fatigue.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          July 31, 2013

                          Lead Product(s) : Iron

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Capital Health, Canada | Dalhousie University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank